These findings demonstrate that the activation of Nrf2 exacerbates liver damage in CLI, and the intervention of Nrf2/HO-1 signaling possesses a potential translational value in the clinical treatment of cholestatic liver disease. This evidence concerns the gene NFE2L2 and Cholestatic liver disease.